Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine

Liang Wang
Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China

Abstract: This article explains the significant role of morphological and functional multidetector computer tomography (MDCT) in combination with imaging postprocessing algorithms served as a problem-solving tool and noninvasive surrogate biomarker to effectively improve hepatic diseases characterization, detection, tumor staging and prognosis, therapy response assessment, and novel drug discovery programs, partial liver resection and transplantation, and MDCT-guided interventions in the era of personalized medicine. State-of-the-art MDCT depicts and quantifies hepatic disease over conventional CT for not only depicting lesion location, size, and extent but also detecting changes in tumor biologic behavior caused by therapy or tumor progression before morphologic changes. Color-encoded parameter display provides important functional information on blood flow, permeability, leakage space, and blood volume. Together with other relevant biomarkers and genomics, the imaging modality is being developed and validated as a biomarker to early response to novel, targeted anti-VEGF(R)/PDGFR or antivascular/angiogenesis agents as its parameters correlate with immunohistochemical surrogates of tumor angiogenesis and molecular features of malignancies. MDCT holds incremental value to World Health Organization response criteria and Response Evaluation Criteria in Solid Tumors in liver disease management. MDCT volumetric measurement of future remnant liver is the most important factor influencing the outcome of patients who underwent partial liver resection and transplantation. MDCT-guided interventional methods deliver personalized therapies locally in the human body. MDCT will hold more scientific impact when it is fused with other imaging probes to yield comprehensive information regarding changes in liver disease at different levels (anatomic, metabolic, molecular, histologic, and other levels).

Keywords: perfusion MDCT, liver nodule, angiogenesis, functional imaging, VEGF receptor

Personalized medicine means tailoring medical care to ensure the delivery of the right therapy for the right patient at the right time based on a patient's unique genetic blueprint.1-3 Personalized medicine based on the cutting-edge technology is already useful in saving patients' lives and reducing healthcare costs and would radically reform the manner of traditional medical practice. Together with other relevant biomarkers and genomics, radiology techniques and imaging methods are the problem-solving tools to help guide treatment to meet the growing demand for patient-individualized treatment that can minimize treatment morbidity while maximizing treatment benefits.4,5 Current innovations in morphological and functional multidetector computer tomography (MDCT) in combination with advance imaging postprocessing algorithms are revolutionizing the traditional interpretation and analysis of radiology examination,
and are being developed and validated as a problem-solving tool and surrogate biomarker for hepatic disease characterization, detection, tumor staging, prognosis, therapy response assessment, novel drug discovery programs, and partial liver resection and transplantation, and MDCT-guided interventions, thus impacting upon personalized medicine.6–8

Unique liver anatomy and kinetics
Analysis of contrast enhancement of the liver is more complex for the following reasons: (1) the sinusoids instead of the capillary, (2) the sinusoidal endothelium (no basement membrane) instead of the capillary endothelium, (3) the space of Disse (or perisinusoidal space) instead of the extravascular extracellular compartment, (4) two blood inflow components in two different time settings to the liver (the hepatic artery and the portal vein), and (5) more challenging due to respiratory motion.

At least, 4 different vascular phases of the liver that should be included are the precontrast, arterial, portal (or equilibrium), and delayed (or venous) phases.1 Hepatic arterial phase occurs at 20–30 seconds post injection (with contrast medium), which provides optimum contrast to the hepatic artery and its branches. Approximately 30% of liver lesions are detectable exclusively on hepatic arterial phase images.10 Hepatic hypervascular lesions reach peak enhancement and are best seen in hepatic arterial phase.11,12 Hepatic portal phase is usually acquired at 30–35 seconds post injection (with contrast medium). Hepatic venous phase at approximately 60 seconds post-injection (with contrast medium), when the contrast material has arrived in the hepatic veins, and hepatic delayed phase 120–180 seconds post-injection (with contrast medium), when contrast-material equilibrium of the intravascular and extravascular components occurs.12 The timing bolus technique and adjustment of the total amount of contrast according to the body weight will compensate for differences in cardiac output and distribution volume.

State-of-the-art MDCT and new-generation iodinated contrast media
With the introduction of modern, fast, dual-source volumetric cine scanners, state-of-the-art MDCT data acquisition has become more robust for qualitative and quantitative analysis.13–16 The advantages of MDCT (64 slices) includes the following: (1) improved spatial/longitudinal resolution (0.4 mm) and increased z-axis coverage (80 mm) using submillimeter collimation, providing an isotropic data set, and reducing partial-volume effects;17,18 (2) shortening of scan time (0.33-second rotation speed of the gantry, <4 seconds for the entire liver) allowing short breath-holding periods, which reduces motion artifacts and provides sharper distinction of each vascular phase;19,20 (3) improved 3D reconstructions for clarification of interfaces predominantly situated in the z-axis, providing clear/detailed distinction of liver lesion12; (4) the ability to apply a multitude of imaging-postprocessing techniques.20,21

Potential biological hazards of radiation associated with MDCT must be considered in achieving both high–temporal resolution and high–spatial resolution imaging of the entire liver. Radiation exposure can be kept under control by using a short scanning time, reduced tube current and tube potential, automatic device-modulating dose delivery in conformity to human body, different X-ray exposure in repeated volume acquisitions.19,22 Currently, commercially available software packages to monitor radiation dosage include WinDose; Wellhofer Dosimetry, Schwarzenbruck, Germany; a cylindrical phantom (Radiation Monitor Controller, model 9015; Radocal Corp, Monrovia, California, USA). To reduce potential biological hazards of radiation, the protocol parameters recommended in hepatic MDCT are slice collimation of 4 × 5 mm, 80–120 kV, 100–200 mA, temporal solution is 4–5 seconds per scan, and weighted CT dose index of 4.16 mGy.22,23

The risk of adverse reaction or renal toxicity of new-generation iodinated contrast media used in MDCT is quite low.24 Moreover, macromolecular contrast media, such as liposomes containing nonionic iodinated contrast media or gold nanoparticles, has longer intravascular half-life and may improve for imaging angiogenesis and perfusion quantification.25–28

Advanced computational image analysis techniques
Advanced computational image analysis techniques have been developed not only to detect liver lesions but also to quantitatively measure liver lesions.29,32 As performed more objectively, reproducibly, and efficiently, especially when attempting to measure volumetrically, the computerized quantitative measurements may ultimately replace manual measurements.31 The clinical application of computational image analysis techniques has substantial implications for monitoring tumor therapy in an individual patient and for evaluating the effectiveness of new therapies under development.29,30,33,34

Various imaging-postprocessing algorithms have been developed to (semi)automatically segment liver contour and liver lesions on MDCT.30,33,35,36 For instance, snake algorithm with gradient vector flow implements liver segmentation.
Shape-constraint region-growing algorithm facilitates automatic delineation of liver lesions and provides unidimension (the largest diameter of the lesion on the transverse image containing the largest cross-sectional area), bidimension (the product of the largest diameter and the largest perpendicular diameter on the same transverse image), and the area on the transverse image for each of the segmented lesions (Figure 1).

Currently, commercially available software packages include Basama Perfusion 3.0.4.8 program (Kanazawa, Ishikawa, Japan); Perfusion CT software (Perfusion 2.0, GE Healthcare, Little Chalfont, Buckinghamshire, UK) with a body tumor perfusion algorithm; AZ-700W (Anzai Medical Co, Ltd, Tokyo, Japan), Syngo Body Perfusion CT (Syngo 2006G; Siemens Medical Solutions, Forchheim, Germany). For example, Perfusion CT software facilitates MDCT data with distributed parameter analysis; Siemens Medical Solutions implements MDCT data with Patlak analysis.

Functional imaging using MDCT and color-encoded parameter display

Functional imaging using MDCT (f-MDCT) has been proposed and evaluated for quantification of the perfusion and enhancement patterns of liver.37,38 By detecting the temporal changes in contrast enhancement from a series of images acquired over time, MDCT can trace tissue and vascular enhancement at small time intervals to capture homodynamic perfusion parameters that reflect useful information on (neo)angiogenesis within a liver lesion for qualitative and quantitative analysis.20,21 Semiquantitative assessments of vascular physiology may be obtained easily.39 The tracer kinetic modeling techniques, such as dual-input single-compartment model, and deconvolution techniques, such as the Johnson/Wilson model, determine liver arterial and portal perfusion, leakage (extracellular) space, capillary permeability, and blood flow/volume.18,40–43

The definitions of semiquantitative/quantitative parameters were summarized in the literature.44 The definitions of the parameters are not further explained in this article. Semiquantitative parameters, such as CT attenuation ($H_0$), time of arrival of contrast agent ($T_0$), relative enhancement, area under the contrast concentration time curve (AUC), wash-in rate, wash-out rate, time between $T_0$ and time of peak CT attenuation (TTP), and brevity of enhancement, are easily derived from CT time–attenuation curve. Quantitative parameters, such as volume transfer constant ($K_{trans}$), rate constant describing transfer of plasma to interstitium space ($K_{ep}$), extracellular extravascular space ($V_e$), vascular permeability–surface area product (PS), blood volume (BV), arterial blood flow (ABF), arterial blood volume (ABV), portal blood flow (PBF), total blood flow (TBF), arterial perfusion rate (APR), hepatic perfusion index (HPI), extraction fraction (EF), and mean transit time (MTT), are obtained by using the compartment pharmacokinetic models such as dual-input single-compartment model and a deconvolution technique.17,41,42,45,46 These parameters are very useful for the estimation of flow through the vessels, venous outflow vascular resistance, capillary wall permeability, composition of the extracellular space, and microvessel density. Standard models require a time course for the plasma concentration of iodine (usually referred to as the arterial input function and portal-venous input function) to calculate the quantitative parameters from CT time–attenuation curve. Due to direct linear relationship between CT attenuation value (expressed in Hounsfield units [HU]) and the plasma concentration of iodine, arterial/portal-venous input function can be measured from a conveniently placed artery/portal vein, respectively. $V_e$ and relative enhancement are highly reproducible on f-MDCT. $K_{trans}$, $K_{ep}$, and wash-in/wash-out rate are sufficiently reproducible but lesser reproducible when compared with $V_e$ and relative enhancement.20 A study suggested maximum slope CT perfusion is more suitable and reproducible than deconvolution CT perfusion.20
Morphological and functional MDCT can be a pixel-wise color-encoded display of various parameters derived from the quantitative data of the CT time–attenuation curve or the compartment pharmacokinetic model. This approach provides an automatic conversion of kinetic contrast information into easy-to-interpret color-scaled images, which provides a quick overview of the degree and heterogeneity of enhancement within the tissue. Pixel-displayed color-coded parameter imaging allows visualization of both anatomical morphology and the enhanced pharmacokinetic parameters, such as blood flow, permeability, leakage space in tumors, and blood volume. Color-coded display of various parameters provides unique insights into tumor structure, function and aggressiveness, and delivery of molecules into the space of Disse, and may therefore be helpful in guiding therapeutic intervention and biopsy sampling and monitoring treatment response. Color-coded parameter images can provide detailed information of the enhancement pattern of focal and diffuse disease processes. Operator-defined region of interest (ROI) analysis can be developed by means of CT time–attenuation curves obtained by placing ROIs on color-coded parameter images. However, color-coded functional images have relatively poor signal-to-noise ratios. The poor signal-to-noise ratios can be overcome by fusing on morphological MDCT.

**Morphological and functional MDCT for hepatic disease and drug discovery**

The currently used nomenclature for hepatocellular focal liver lesions identifies 2 types of liver lesions: regenerative and neoplastic or dysplastic lesions.44–49 Regenerative lesions include regenerative nodules, segmental or lobar hyperplasia, and focal nodular hyperplasia (FNH). Neoplastic or dysplastic lesions include hepatocellular adenoma, dysplastic foci, dysplastic nodules, and hepatocellular carcinoma (HCC). Common hepatocellular lesions with benign growth behavior include cysts, hemangiomas, FNH, and hepatocellular adenomas, although the latter is rarely associated with malignant transformation.49 Diffuse liver parenchymal abnormalities include a wide variety of disease entities, such as hepatitis, cirrhosis, hemochromatosis, steatosis, and diffuse malignancies.

**Characterization and detection of focal liver lesions**

The vast majority of hemangiomas show a typical peripheral nodular enhancement pattern on relative-enhancement image from hepatic arterial phase and persistent fill-in of the entire lesion over time on relative-enhancement image from hepatic delayed phase. Characteristically, liver adenomas show a transient blush on the relative-enhancement image from hepatic arterial phase, and fade to iso-attenuation on the relative-enhancement image from hepatic delayed phase. In case of previous hemorrhage, adenoma can be inhomogeneous on the relative-enhancement image from hepatic arterial phase. Typically, FNH shows very intense homogeneous enhancement on the relative-enhancement image from hepatic arterial phase and iso-attenuation on the relative-enhancement image from hepatic delayed phase. The central scar of FNH is enhanced on the relative-enhancement image from hepatic delayed phase. Dysplastic nodules, especially high-grade dysplastic nodules, are premalignant lesions that can demonstrate enhancement on the relative-enhancement image from hepatic arterial phase. HCC (also called malignant hepatoma) typically shows intense and early enhancement on wash-in rate, $T_0$, TTP, and relative-enhancement image from hepatic arterial phase, and much of the contrast lost on wash-out rate or relative-enhancement image from hepatic delayed phases. In hepatic delayed phases, many HCCs show enhancement of a tumor capsule.23,44 Relatively higher and more variable perfusion parameters (BF, BV, HPI, AP, PS) and a lower MTT and PP values compared with background liver were observed in well-differentiated HCC compared with those in moderately/poorly differentiated (angioinvasive) HCC.37,50 Sahani et al.17 demonstrated that f-MDCT parameters (BF, BV, PS, MTT) are reproducible and have good correlation ($r = 0.9$) in quantifying tumor vascularity and angiogenesis in advanced HCC. Fibrolamellar HCC may show some overlap with FNH, including arterial enhancement and presence of a fibrous central scar. Important differences between FNH and fibrolamellar HCC include the following: (1) on relative-enhancement image from hepatic arterial phase, a more pronounced and homogeneous enhancement for FNH, and a heterogeneous, less pronounced enhancement for fibrolamellar HCC; and (2) on relative-enhancement image from hepatic delayed phase, presence of washout in fibrolamellar HCC and persistent higher CT attenuation in FNH. The degree of enhancement of hypovascular liver metastases can be similar to the surrounding liver on the relative-enhancement image from hepatic arterial phase, but hypovascular liver metastases typically show lower enhancements than the surrounding liver and often show a peripheral irregular ring of enhancement on the relative-enhancement image from hepatic portal phases. The periphery of liver metastases often has a higher wash-in rate than the center of the lesion on imaging. Hypovascular liver metastases shows
slightly delayed enhancement, and the liver lost some of its contrast. Therefore, the conspicuity of lesion has decreased. Hypervascular liver metastases are derived from highly vascular tumors, such as breast carcinoma, thyroid carcinoma, carcinoid, islet cell tumor, renal carcinoma, melanoma, pheochromocytoma. Small liver metastases often show intense enhancement, whereas, large liver metastases may only display enhancement in the peripheral rim. Significant changes in perfusion parameters (earlier \( T_0/\text{TTP} \), increased ABF/ABV/HPI/PS/wash-in rate) were color-coded image in hypervascular liver metastases owing to the increased hepatic arterial component, as well as arteriovenous shunting in tumor. Metastases (micro) can be identified as areas of high perfusion on HPI image. f-MDCT even display occult hepatic metastases. The increase in ABF within the metastasis (especially the adjacent liver) is correlated with the patient’s survival time.

Reported sensitivity of MDCT varies widely, with values of 6%–89% for the detection of HCC. Relatively high sensitivity (74%–85%) for metastatic liver tumors has been reported. Primary and metastatic liver malignancies and cirrhosis can be earlier detected based on relative increases in HBF. Diagnostic sensitivity and accuracy of MDCT are significantly improved and result in better detection of hepatic lesions, thus decreasing the number of biopsies.

**Evaluation of diffuse liver disease and hepatic perfusion disorder**

Diffuse liver parenchymal diseases consist of various disease processes, such as cirrhosis, infectious and inflammatory diseases, storage diseases, vascular diseases, and diffuse malignancies. Significant changes in perfusion parameters (increased ABF/BV/MMT, and decreased PBF/TBF) were observed in cirrhosis as a result of excessive deposition of collagen in the space of Disse and defenestration of the basal lamina, sinusoids. Moreover, the changes in the perfusion parameters correlated with the severity (the degree of fibrosis) of chronic liver disease. Acute hepatitis may present with heterogeneous patchy enhancement of the affected liver parenchyma in hepatic arterial phase and becomes occult in hepatic portal and delayed phases. MDCT have been applied to evaluate hepatic functional reserve and liver volume variation in patients with chronic liver diseases. Hepatic perfusion disorders are related to a variety of disease entities or anatomic variants, such as portal venous obstruction, arterial obstruction, hepatic venous obstruction (eg, Budd–Chiari syndrome, heart failure, mediastinal fibrosis), mediastinal or thoracic venous inlet obstruction, focal liver lesions, inflammatory processes, normal anatomic variants in the hepatic blood supply, altered anatomic variants in the placement of a transjugular intrahepatic portosystemic shunt, and uncertain causes. Hepatic perfusion disorders (except siphoning effect, severe hepatic artery stenosis or occlusion, hepatic infarct, and Budd–Chiari syndrome) typically presents high enhancement of the affected liver parenchyma on the relative-enhancement image from hepatic arterial phase, and iso-enhancement of the affected liver parenchyma on the relative-enhancement image from hepatic portal phase. Arterioportal shunt shows early enhancement of the peripheral portal vein branches and transient enhancement of peripheral wedge-shaped affected liver parenchyma with a clear margin on the relative-enhancement image from hepatic arterial phase. Severe hepatic artery stenosis or occlusion and hepatic infarction typically demonstrate a wedge-shaped diminished enhancement of the affected liver parenchyma on the relative-enhancement image from hepatic arterial phase and hepatic portal phase, respectively. Budd–Chiari syndrome demonstrate heterogeneous and mosaic enhancement pattern and absence of hepatic vein enhancement on the relative-enhancement image from hepatic arterial phase and from hepatic portal phase.

**Tumor staging and prognosis**

The tumor-node-metastasis (TNM) staging system is widely used to stage liver cancer. The up-to-date edition of *AJCC Cancer Staging Manual* becomes effective in 2010 (Table 1). Morphological and functional MDCT findings compose crucial elements in defining the TNM stage of HCC. MDCT provided the accurate stage of disease in 46% of cirrhotic candidates for liver transplantation. Progressive disease had lower baseline MTT values and a higher percent increase after bevacizumab therapy than stable disease or partial response in patients with advanced HCC.

**Monitoring therapy response and novel drug discovery programs**

Accurate therapy response assessment is important for judging the outcome of therapy. Early selection of patients who are most likely to benefit from a specific type of therapy would prevent time consumption, money, and unnecessary drug toxicity in nonresponding patients. Direct pathological measurement of tumor, such as tumor microvessel density (MVD), in biopsy specimens provides potentially unreliable information of the vessel function. Together with other relevant biomarkers and genomics, morphological and functional MDCT, based on therapy response criteria, has been
Moreover, recently, the new agents such as cytostatic (halting tumor growth) agents, epidermal growth factor receptor, tyrosine kinase inhibitors, such as gefitinib and erlotinib, or antiangiogenic (inhibiting or disrupting tumor neovascularure growth) agents, such as bevacizumab (Avastin, Genentech/Roche), have been shown to increase survival in patients with hepatic malignancies when combined with standard cytotoxic (causing tumor shrinkage) therapies. After being treated with these newer agents, tumors respond by undergoing cystic change and central necrosis that may not be captured by the WHO or RECIST response criteria. Modified response criteria for patients with HCC and gastrointestinal stromal tumor incorporate tumor functional information and the extent of macroscopic tumor necrosis or cystic changes on imaging such as MDCT that could improve conventional RECIST criteria. European Association for the Study of the Liver (EASL) criteria uses the reduction in viable tumor volume to assess tumor response by using the reduction in viable tumor volume. Residual tumor and the extent of tumor necrosis can be evaluated using EASL.

Tumor morphological change on MDCT is important information to monitor therapy response and novel drug discovery programs. A study of 68 patients with metastatic colorectal cancer on clinical trials of hepatic arterial infusion of floxuridine and dexamethasone with systemic oxaliplatin with 5FU/LV and/or irinotecan demonstrated that there was a 92.6% agreement rate and a 7.4% disagreement rate in best overall response found an average robustness of response between RECIST and WHO. Mean percentage decrease in tumor size among the 27 unidimensional responders and 28 bidimensional responders was 65.0% and 79.7%, respectively. Mean increase in the tumor size among the 36 unidimensional progressors and 48 bidimensional progressors was 61.8% and 139.1%, respectively. The average robustness value was −35.3% by RECIST and 53.9% by WHO among the 17 discordant pairs and −25.9% by RECIST and 78.9% by WHO among the 51 discordant pairs. A comparison of robustness of response in time to best overall response found an average robustness value of 35.7% by RECIST vs 24.8% by WHO among the 10 discordant cases and 5.3% by RECIST vs 60.6% by WHO among the 58 discordant cases. Time to tumor progression was different between WHO and RECIST (P = 0.006). The authors concluded that this may impact clinical trials, whose results are interpreted with RECIST and WHO. A new method of measuring robustness of response may indicate disease sites or therapies that are affected by measurement technique, and help to define the degree of response or progression. A study of 70 patients demonstrated that the optimal duration of chemotherapy (significant reduction

### Table 1 Tumor node metastasis staging of liver cancer (American Joint Committee on Cancer 7th edition, 2010)

<table>
<thead>
<tr>
<th>Primary tumor (T)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX: Primary tumor cannot be assessed</td>
</tr>
<tr>
<td>T0: No evidence of primary tumor</td>
</tr>
<tr>
<td>T1: Solitary tumor without vascular invasion</td>
</tr>
<tr>
<td>T2: Solitary tumor with vascular invasion or multiple tumors none more than 5 cm</td>
</tr>
<tr>
<td>T3a: Multiple tumors more than 5 cm</td>
</tr>
<tr>
<td>T3b: Single tumor or multiple tumors of any size involving a major branch of the portal or hepatic veins</td>
</tr>
<tr>
<td>T4: Tumor(s) with direct invasion of adjacent organs other than gallbladder or with perforation of visceral peritoneum</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regional lymph nodes (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX: Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0: No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1: Regional lymph node metastasis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distal metastasis (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX: Distal metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0: No distal metastasis</td>
</tr>
<tr>
<td>M1: Distal metastasis</td>
</tr>
</tbody>
</table>

**Note:** The system only applies to hepatocellular carcinoma staging and no longer applies to intrahepatic cholangiocarcinoma staging. Sarcoma and tumors metastatic to the liver are not included. Inferior phrenic lymph nodes were reclassified into regional lymph nodes from distant lymph nodes. Copyright © 2010. Reprinted with permission from Edge SB, Byrd DR, Carducci MA, Compton CC, editors. AJCC Cancer Staging Handbook. 7th ed. New York: Springer-Verlag; 2010.

**Abbreviation:** TNM, tumor node metastasis.

The up-to-date RECIST (version 1.1) becomes essential to determine whether the therapy is beneficial to the patient, to help make clinical decisions, and for the development and approval of new anticancer drugs. However, the WHO/RECIST criteria have not taken functional or volumetric information into consideration. Firstly, in tumor size due to tumor shrinkage in one or two dimensions may not always provide adequate and timely information on tumor response to therapy. Morphologic findings may lag chronologically or even fail to correspond to the patient’s clinical response and functional changes in tumors, and thus may not be able to adequately capture the effects of novel therapies. Secondly, in tumor size may not provide accurate prognosis for an individual patient. RECIST alone cannot be used to evaluate local treatment of tumors by cryoablation or radiofrequency ablation. The average robustness value was −35.3% by RECIST and 53.9% by WHO among the 17 discordant pairs and −25.9% by RECIST and 78.9% by WHO among the 51 discordant pairs. A comparison of robustness of response in time to best overall response found an average robustness value of 35.7% by RECIST vs 24.8% by WHO among the 10 discordant cases and 5.3% by RECIST vs 60.6% by WHO among the 58 discordant cases. Time to tumor progression was different between WHO and RECIST (P = 0.006). The authors concluded that this may impact clinical trials, whose results are interpreted with RECIST and WHO. A new method of measuring robustness of response may indicate disease sites or therapies that are affected by measurement technique, and help to define the degree of response or progression. A study of 70 patients demonstrated that the optimal duration of chemotherapy (significant reduction
in tumor size on MDCT scans) was 2–4 months prior to liver resection for colorectal liver metastases. In a phase 2 study of sorafenib (an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases) in 137 patients with inoperable HCC, baseline and serial follow-up MDCT scans demonstrated tumor necrosis, overall tumor response, time to progression, and overall survival. A study of 23 patients with advanced HCC treated with MDCT and sunitinib after radiation therapy demonstrated a high RECIST with an objective response in 74% of patients. A study of 34 patients with metastatic colorectal cancer on clinical trials of floxuridine and dexamethasone with 5FU/LV or intravenous oxaliplatin and irinotecan demonstrated a 97% agreement rate in best overall response between unidimensional and bidimensional measurements. The authors concluded that there is a high concordance in the best overall response classification between WHO and RECIST. However, time to progression and time to best overall response/nadir is different. This information should be considered in clinical trial design, clinical trial interpretation, in the interpretation of a given patient’s response (or apparent lack of response) to therapy, and in the development of anticancer drugs. This work provided a new avenue for study of colorectal carcinoma therapy assessment, which had troubled colorectal carcinoma research and clinical practice for decades and had a great impact on the research and clinical practice in this field worldwide.

Tumor functional change, such as the decrease in hemodynamic blood flow parameters and tumor microvessel density on f-MDCT, after administration of anti-angiogenesis drugs (bevacizumab, cediranib [Recentin®, AZD2171, AstraZeneca plc, Westminster, London], SU6668 [Pfizer, New York, USA], Sorafenib [Nexavar®; Bayer Healthcare],

| Table 2 Comparison of WHO response criteria and RECIST 1.0 and RECIST 1.1

<table>
<thead>
<tr>
<th>WHO</th>
<th>RECIST 1.0</th>
<th>RECIST 1.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor size calculation methods</td>
<td>Measurable: Bidimensional (the cross product of the longest diameter and the longest perpendicular diameter). Lesion number: not specified.</td>
<td>Measurable: Unidimensional (the longest diameter). Lesion size: ≥10 mm (spiral CT); ≥20 mm (nonspiral CT); Lesion number: ≥10 lesions (S/organ).</td>
</tr>
<tr>
<td>Response criteria</td>
<td>Nonmeasurable: e.g. lymphangitic pulmonary metastases.</td>
<td>Nonmeasurable: All other lesions including small lesions.</td>
</tr>
<tr>
<td></td>
<td>Measurable: PD: ≥25% increase of at least one measurable lesion or appearance of new lesions; CR: disappearance of all known disease (confirmed at least 4 wk later); PR: ≥50% decrease from baseline (confirmed at least 4 wk later); NC: neither PR nor PD criteria met.</td>
<td>Target: PD: ≥20% increase in sum of longest diameter from nadir or appearance of new lesions; CR: disappearance of all known disease (confirmed at least 4 wk later); PR: ≥30% decrease from baseline (confirmed at least 4 wk later); SD: neither PR nor PD criteria met.</td>
</tr>
<tr>
<td></td>
<td>Nonmeasurable: PD: ≥25% increase of existent lesions or new lesions; CR: disappearance of all known disease (confirmed at least 4 wk later); PR: ≥50% decrease from baseline (confirmed at least 4 wk later); NC: neither PR nor PD criteria met.</td>
<td>Nonmeasurable: CR: disappearance of all nontarget lesions and normal tumor markers (confirmed at least 4 wk later); non-PD: persistence of one or more nontarget lesions or tumor marker abnormal elevation.</td>
</tr>
<tr>
<td>Lesion number:</td>
<td>not specified.</td>
<td>Lesion number:</td>
</tr>
<tr>
<td>Lesion size:</td>
<td>10 lesions</td>
<td>15 mm short axis is CR.</td>
</tr>
<tr>
<td>Morphological and functional MDCT</td>
<td>Lesion size:</td>
<td>Lesion size:</td>
</tr>
<tr>
<td>10 mm (nonspiral CT);</td>
<td>5 mm or more nontarget lesions or tumor marker abnormal elevation.</td>
<td>10 mm short axis is CR.</td>
</tr>
</tbody>
</table>

Abbreviations: WHO, World Health Organization; RECIST, Response Evaluation Criteria in Solid Tumors; CT, computed tomography; PD, progressive disease; CR, complete response; PR, partial response; NC, no change.
and sunitinib [Sutent, SU11248]), antivascular endothelial growth factor (receptor) or platelet-derived growth factor receptor (VEGF(R)/PDGFR) agents, or antivascular drugs (such as endostatin) is concordant with that on other imaging studies, such as magnetic resonance imaging (MRI) or positron emission tomography (PET).20,91,92 Functional changes may be earlier or more specific than anatomic morphological changes after antiangiogenic/vascular or anti-VEGF(R)/PDGFR drugs.18 The use of f-MDCT provides accurate quantification of perfusion function of mature vessels without changes of MVD after antiangiogenic treatment with SU5416.93 In a study of 16 patients with liver metastatic lesion of renal cell carcinoma after thalidomide therapy, the decrease in perfusion parameters (BF, BV, MTT, PS) were color-coded imaged, time to progression correlated with BF and PS, and responders had a higher decrease in BF than the nonresponders.54 A study of 33 patients with measurable locally advanced, recurrent, or metastatic HCC demonstrated a significant decrease in BF, BV, and PS in HCC and an increase in MTT on f-MDCT after bevacizumab therapy.97 Quantification of hepatic blood flow on f-MDCT may also be useful to assess vascular changes secondary to interventional therapies, earlier identification of tumor recurrence, and liver graft rejection in transplant patients.23,94 The substantial increase in ABF and TBF (but PBF remained unchanged) in transjugular intrahepatic portosystemic shunt placement was observed on f-MDCT.60 f-MDCT provides accurate and reproducible quantification of liver tumor perfusion after transcatheter arterial chemoembolization procedure.95 A study of 13 patients treated with a combination of AZD2171 (AstraZeneca, Wilmington, Delaware, USA) and gefitinib (Iressa®, ZD1839; AstraZeneca) demonstrated an initial decrease of 39% in wash-in rate within the liver tumors and 36% in wash-in rate within a rim region surrounding the tumors, followed by a trend toward recovery of hepatic artery flow detected by f-MDCT.28

Partial liver resection and transplantation
Morphological and functional MDCT have been applied to evaluate hepatic function in partial liver resection and transplantation.96,97 CT volumetry, in which liver volume is the established method to assess future remnant liver function assessment before partial hepatectomy, follow-up after preoperative portal vein embolization, postoperative liver regeneration, and graft function.98–101 However, the correlation coefficient between the postoperative indocyanine green (ICG) clearance predicted by MDCT and the actual postoperative ICG clearance is moderate.106,107 Three-dimensional algorithms have been developed to calculate metabolic liver volume and nonmetabolic liver volume on MDCT.102,108,109

MDCT-guided interventions
MDCT-guided interventional methods have been applied to deliver personalized therapies locally in the human body.110–113

Parallel imaging modalities and “fused” imaging modalities
As with MDCT, several imaging modalities, such as ultrasound, MRI, single-photon emission computed tomography (SPECT), and PET, have been used for hepatic disease and drug discovery. Ultrasound can be applied for quantification by means of Doppler ultrasonography or contrast-enhanced ultrasound or ultrasound elasticity.114,115 However, the main limitation of ultrasound examinations is that it is operator dependent, hence with low reproducibility and has low sensitivity.116 Doppler ultrasound assesses morphological and hemodynamic changes of liver circulation. With the introduction of second-generation microbubble contrast media, contrast-enhanced ultrasound characterizes enhancement patterns of hepatic lesions, similar to that achieved with f-MDCT and dynamic contrast-enhanced MRI (DCE-MRI). Transient elastography (FibroScan™, Echosens, Paris, France) is a novel method for the evaluation of hepatic fibrosis in patients with chronic liver diseases.117–119 MRI has superior soft-tissue contrast resolution, lacks ionizing radiation, and has the possibility of performing functional and metabolic imaging sequences, which are particularly advantageous for serial examinations to monitor therapy response and the whole liver surveillance of HCC and hepatic dysplastic nodules. Compared with MRI, scintigraphy, and PET, MDCT has the highest spatial resolution, it is less cost and time consuming, and it is broadly available. However, radiation doses must be considered. The choice between MDCT and MRI depends on machine availability, doctor expertise, tumor location, desired parameters, and the requirement of decreased radiation burden.120,121 DCE-MRI, with f-MDCT, studies hepatic perfusion, tumor capillary wall permeability, and biliary excretion using different kinds of contrast media.122–124 Both DEC-MRI and f-MDCT are easily incorporated into routine examinations.120 There are differences between the 2 imaging modalities in acquisition techniques, mathematical analysis, and propensity to artifacts.120 f-MDCT may be more
quantitative and more reproducible than DCE-MRI. Diffusion-weighted imaging (DWI) and diffusion tensor imaging measure the Brownian motion of water molecules in biologic tissues. The apparent diffusion coefficient (ADC) derived from DWI and diffusion tensor imaging, has been in use for the quantitative assessment of tissue diffusivity. DWI demonstrated no or minimal signal decrease from b of 0 s/mm$^2$ to a higher b value, reduced ADC, and increased fractional anisotropy in malignant lesion. DWI and diffusion tensor imaging still have poor SNR, limited spatial resolution, and ADC reproducibility. MR spectroscopy (MRS) investigates metabolism for diffuse and chronic liver diseases, congenital diseases, diabetes, and cancer. MRS can quantify liver fat by measuring choline peak, lactate/pyruvate ratios, and diagnose liver dysfunction by measuring 31P metabolites. MRS imaging has a rather low spatial resolution and still mainly used as a clinical research tool. MR elastography noninvasively assesses the viscoelasticity of tissues and has been applied to detect and stage liver fibrosis, which increases hepatic stiffness or elasticity. SPECT is obtained after intravenous injection of a radiopharmaceutical agent, such as technetium 99m–labeled, sulfur pertechnetate, DTPA-galactosyl albumin, 150–158 99mTc-GSA scintigraphy (receptor mediated) and 99mTc-mebrofenin HBS (hepatic uptake and excretion) reliably assess hepatic function and functional reserve. Several studies demonstrated that 99mTc-GSA scintigraphy has a strong correlation with ICG clearance test and holds incremental value over CT volumetry for predicting remnant liver function. Metabolic imaging with PET is performed after the intravenous injection of radiotracers, such as 18FDG, 11C-acetate, 62Cu-PTSM, and C15O2, to evaluate cancer metabolism, endocrine status, hypoxia, and oncofetal and differentiation antigens. The degree of changes in tumor glucose metabolism determined by 18F-FDG PET is predictive of patient outcome. Semiquantitative measurements (eg, standardized uptake value [SUV]) and full kinetic quantitative analyses have been developed to measure the rate of glucose metabolism. SPECT and PET have inadequate spatial resolution compared with MRI and CT.

“Fused” or “hybrid” imaging modalities, such as ultrasonography/CT, SPECT/CT, PET/CT, and f-CT/PET/CT, integrate advantages of different modalities yielding comprehensive information regarding changes in liver disease at different levels (anatomic, metabolic, molecular, histologic, and other levels). PET/MRI is the next generation of clinical imaging multimodality, which may not only provide the potential to provide more anatomical, functional, metabolic, and molecular details than MDCT, especially when scanning soft tissue, but also considerably lower radiation exposure compared with PET/CT. However, the development of PET/MRI system is technically more challenging, and the cost of PET/MRI would be likely higher.

In summary, as the era of personalized medicine is approaching, morphological and functional MDCT, together with other relevant biomarkers and genomics, serves as a problem-solving tool and surrogate biomarker for hepatic disease characterization, detection, tumor staging and prognosis, therapy response assessment, novel drug discovery programs, partial liver resection and transplantation, and CT-guided interventions. Analysis of color-coded images offers an easy-to-interpret presentation of hepatic disease behavior changes on blood flow, permeability, leakage space, and blood volume. Fused imaging modalities, such as ultrasonography/CT, SPECT/CT, PET/CT, and f-CT/PET/CT, yield comprehensive information regarding changes in liver disease at different levels (anatomic, metabolic, molecular, histologic, and other levels). It is critical for the development of computational image analysis techniques for MDCT to detect and define liver cancer, which would be helpful in presurgical planning for hepatic resection and to gauge the results of therapies.

**Conclusion**

In the era of personalized medicine, advanced morphological and functional MDCT in combination with imaging postprocessing algorithms, together with other relevant biomarkers and genomics, serves as a noninvasive problem-solving tool and surrogate biomarker to effectively improve hepatic disease characterization, detection, tumor staging prognosis, therapy response assessment, novel drug discovery programs, partial liver resection and transplantation, and CT-guided interventions.

**Abbreviations**

- $T_p$: time of arrival of contrast agent; $H_p$: CT attenuation (expressed in HU) prior to contrast agent; TTP, time between $T_p$ and time of peak CT attenuation; AUC, area under the contrast concentration time curve; IAUC, initial area under the contrast concentration time curve; BF, blood flow; ABF, arterial blood flow; PBF, portal blood flow; TBF, total blood flow; ABV, arterial blood volume; APR, arterial perfusion rate; HPI, hepatic perfusion index; AP, arterial perfusion; PP, portal perfusion; SPV, standardized perfusion values; BV, blood volume; MTT, mean transit time; PS, vascular permeability–surface area product; $V_{e}$, extracellular extravascular space; $k_{ep}$ (or $K_{21}$), rate constant describing
transfer of plasma to interstitium space; \( rBV \), relative blood volume; \( v_{\text{trans}} \), volume transfer constant; \( k_{\text{d}} \), rate of clearance of contrast agent from the vascular compartment; \( K_{\text{d}} \), bidirectional transfer constant; EF, extraction fraction; RECIST, Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization; EASL, European Association for the Study of the Liver; VEGF(R), vascular endothelial growth factor receptor; PDGF, platelet-derived growth factor receptor; AZD2171, an oral tyrosine kinase inhibitor of the vascular endothelial growth factor receptor-2 (VEGFR-2) with additional inhibitory activity to VEGFR-1 and VEGFR-3; thalidomide, inhibitor of TNF-\( \alpha \), interleukins, and interferons; TNF, tumor necrosis factor; ROI, region of interest; AJCC, American Joint Committee on Cancer, f-MDCT, functional multidetector computed tomography; GIST, gastrointestinal stromal tumor; MVD, blood vessel density; TNM, tumor node metastasis; ICG, indocyanine green.

### Disclosure

The author reports no conflict of interest in this work.

### References


97. Soyer P, Roche A, Elias D, Levesque M. Hepatic metastases from hepatic metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not every-


